ImmunityBio’s Lynch Syndrome Vaccine Trial

Photo of author
Written By Joel Gbolade

ImmunityBio, a leading figure in clinical-stage immunotherapy, recently announced a significant milestone in cancer prevention research. 

The company has successfully completed the enrollment of the initial two phases of a crucial trial aimed at evaluating the efficacy of its innovative Nant Cancer Vaccine (NCV) in individuals with Lynch Syndrome. 

This advancement marks the transition to the critical randomized controlled phase of the trial, a step that could redefine approaches to cancer prevention.

Understanding Lynch Syndrome and the Trial’s Significance

Lynch syndrome, a genetic condition affecting an estimated one million Americans, significantly increases the risk of developing various cancers at a younger age. 

Credit: DepositPhotos

This trial, focusing on ImmunityBio’s NCV—a combination of a tri-valent Adenovirus (Tri-Ad5) and the IL-15 superagonist N-803—aims to explore a pioneering method to prevent colon and other cancers in those predisposed due to Lynch Syndrome.

Read More: Arbor Realty Trust Surpasses Q2 Earnings and Revenue Forecasts, Signaling Strong Performance

The Mechanics of the NCV

The trial’s innovative approach utilizes a second-generation Adenovirus vector to deliver a tri-valent combination of antigens, designed to activate the body’s natural killer (NK) and T cells. 

This mechanism targets cancer-specific proteins, potentially halting the progression of precancerous cells into full-blown cancer. The inclusion of the IL-15 superagonist N-803 is intended to amplify this response, enhancing the vaccine’s preventive capabilities.

The Trial’s Progress and Future Prospects

With the first 20 participants already enrolled, the study has completed its initial open-label phases. It now progresses to a randomized controlled phase, with a total of 186 individuals slated for enrollment. 

This phase will see participants randomized to receive either the NCV or a placebo, providing crucial data on the vaccine’s effectiveness in cancer prevention.

Also Read: Will Qurate Retail Group Bounce Back After Making Key Strategic Moves? 

A Focus on Collaboration and Innovation

The trial, sponsored by the National Cancer Institute, part of the National Institutes of Health, represents a collaborative effort to tackle cancer’s hereditary aspects. 

Dr. Patrick Soon-Shiong, Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio, expressed enthusiasm about the study’s potential to harness the immune system for cancer prevention in genetically at-risk populations.

Addressing a Critical Need

The rapid enrollment of participants underscores the urgent need for innovative cancer prevention strategies. Lynch syndrome carriers, who are significantly more likely to develop certain cancers, represent a population in desperate need of effective prevention methods. 

This study not only addresses this need but also contributes to the broader understanding of cancer’s hereditary factors.

A New Dawn in Cancer Prevention

ImmunityBio’s trial stands at the forefront of cancer research, offering a glimpse into the future of preventing inherited cancers. 

As the study moves into its randomized controlled phase, the scientific community and potential participants watch closely, hopeful for positive outcomes that could revolutionize cancer prevention for those with Lynch Syndrome and beyond.

Credit: DepositPhotos

This trial not only signifies a step forward in scientific innovation but also embodies the collective aspiration for a future where hereditary cancers can be effectively prevented, altering the lives of thousands annually.

ImmunityBio Stock currently trades at just under $6 per share and has increased in value by almost 30% in the past month.

Read Next: AbCellera Biologic’s 5.6% Share Increase Shows Promise: Will The Stock Continue to Run?


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.